Dexcom G7 Accuracy and Reproducibility in the Intensive Care Unit
Dexcom G7: Genauigkeit und Reproduzierbarkeit auf der Intensivstation
Diabetes Technology & Therapeutics · 2025-09 · 27 (9) · 747-752
DOI: 10.1089/dia.2025.0184 ↗Auf einen Blick
In einer prospektiven Studie mit 30 Intensivpatient:innen war die Genauigkeit des Dexcom G7 etwas geringer als die Zulassung für den ambulanten Einsatz, aber ähnlich wie außerhalb der ICU.
Fragestellung
Wie genau ist der Dexcom G7 auf der Intensivstation?
Methode
Prospektive Single-Center-Studie bei mit Insulin behandelten Patient:innen mit Diabetes oder Stresshyperglykämie; zwei Sensoren am Abdomen und/oder Oberarm; Vergleich mit BG-Messungen im üblichen ICU-Setting.
Ergebnisse
30 Teilnehmende, 1.515 Sensor-BG-Paare. Bias −12 mg/dL (Median −6), RAD 16 % (Median 12 %). Mit Plasma als Referenz RAD 13 %; mit Kapillarblut 17 %. In 35 Nicht-ICU-Erwachsenen mit Typ-2-Diabetes lag der RAD bei 15 %.
Schlussfolgerung der Autor:innen
Der mittlere RAD des Dexcom G7 auf der Intensivstation war etwas höher als die Kennzeichnung für den ambulanten Gebrauch, aber ähnlich wie in einem nicht-ICU-Hospitalsetting.
Kernaussagen
- 30 Intensivpatient:innen mit Diabetes oder Stresshyperglykämie
- RAD 16 %; Bias −12 mg/dL
- Ähnlich wie im nicht-ICU-Hospitalsetting
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 27.08.2025. Verfasst von Jesica D Baran und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Intensive Care Units, Blood Glucose, Hyperglycemia, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS.
Themen: Intensivpflege
Abstract (Originalsprache)
Objective
To evaluate the accuracy of Dexcom G7 continuous glucose monitor (CGM) in the intensive care unit (ICU) setting.
Methods
We performed a prospective, single-center study in patients with known diagnosis of diabetes or stress hyperglycemia and treated with insulin. Two Dexcom G7 sensors were placed on the abdomen and/or upper arm. Blood glucose (BG) measurements obtained according to usual ICU care were paired with sensor glucose values, and accuracy metrics were analyzed. For further comparison, non-ICU patients were also studied.
Results
The analyses included 30 participants with mean ± standard deviation age of 55 ± 12 years, with preexisting diabetes in 40% and stress hyperglycemia in 60%. A total of 1515 sensor-BG pairs were analyzed. The mean difference (bias) was −12 mg/dL (median: −6), and the mean relative absolute difference (RAD) was 16% (median: 12%). Mean RAD was 13% (median: 9%) using plasma glucose as the reference and 17% (median: 13%) using capillary glucose. For comparison, in 35 adults with type 2 diabetes in a non-ICU setting, the mean RAD was 15% (median: 13%). No meaningful differences were observed across the duration of time since sensor insertion. No correlation was found between mean RAD and severity of illness.
Conclusions
Mean RAD of the Dexcom G7 sensor in the ICU setting was slightly higher than the outpatient use labeling, but was similar to a non-ICU hospital setting. Further studies are needed to determine whether CGM can be used nonadjunctively in an ICU setting for insulin management, including use of glucose trends and alarms for hypoglycemia or hyperglycemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Washington, Seattle, Washington, USA.
- Jaeb Center for Health Research, Tampa, Florida, USA.
- Emory University, Atlanta, Georgia, USA.
- University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- University of North Carolina, Chapel Hill, North Carolina, USA.
- University of Colorado, Aurora, Colorado, USA.
ORCID-Profile: Hou-Hsien Chiang, Francisco J Pasquel, Roy W Beck, Irl B Hirsch
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
Zitieren
APA
Baran, J. D., Spanbauer, C., Bais, R., Chiang, H. H., Chao, J. H., Khakpour, D., Panfil, P., Pasquel, F. J., Ullal, J., Gligorijevic, N., Jones, M. S., Low Wang, C. C., Buse, J. B., Draznin, B., Sibayan, J., Kollman, C., Beck, R. W., Hirsch, I. B., & TIGHT RCT Study Group (2025). Dexcom G7 Accuracy and Reproducibility in the Intensive Care Unit. Diabetes Technology & Therapeutics, 27(9), 747-752. https://doi.org/10.1089/dia.2025.0184
Vancouver
Baran JD, Spanbauer C, Bais R, Chiang HH, Chao JH, Khakpour D, et al. Dexcom G7 Accuracy and Reproducibility in the Intensive Care Unit. Diabetes Technology & Therapeutics. 2025;27(9):747-752. doi:10.1089/dia.2025.0184
BibTeX
@article{Baran2025,
author = {Baran, Jesica D and Spanbauer, Charles and Bais, Rajlaxmi and Chiang, Hou-Hsien and Chao, Jing H and Khakpour, Dori and Panfil, Patrisia and Pasquel, Francisco J and Ullal, Jagdeesh and Gligorijevic, Nikola and Jones, Morgan S and Low Wang, Cecilia C and Buse, John B and Draznin, Boris and Sibayan, Judy and Kollman, Craig and Beck, Roy W and Hirsch, Irl B and TIGHT RCT Study Group, TIGHT RCT Study Group},
title = {Dexcom G7 Accuracy and Reproducibility in the Intensive Care Unit},
journal = {Diabetes Technology & Therapeutics},
year = {2025},
volume = {27},
number = {9},
pages = {747--752},
doi = {10.1089/dia.2025.0184}
}
EUVIMED